Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.
Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...
A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...
Prostate cancer presents challenges in detection, treatment, and management. Learn about genetic risks, treatment resistance, ...
A groundbreaking, hour-long procedure using electrical currents to eliminate hard-to-reach prostate tumors is providing ...
Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
Prostate cancer remains one of the most prevalent cancers among men worldwide. For patients with advanced or metastatic ...
Black men have higher rates of stage 3 and stage 4 prostate cancer diagnosis compared to white men, a study has suggested. The analysis of data from the National Prostate Cancer Audit by the charity ...
Prostate cancer stands as the third most common cancer among Malaysian men, with 70 percent of cases diagnosed at advanced ...